Global Information
회사소개 | 문의 | 비교리스트

PD-1/PDL-1 억제제 시장 - 세계 및 지역별 분석 : 적응증별, 제품별, 지역별 - 분석과 예측(2022-2032년)

PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032

리서치사 BIS Research Inc.
발행일 2022년 09월 상품코드 1123672
페이지 정보 영문 배송안내 1-2일 (영업일 기준)
가격
US $ 5,250 ₩ 7,596,000 PDF and Excel (1-3 User License)
US $ 8,100 ₩ 11,719,000 PDF and Excel (Global License)


PD-1/PDL-1 억제제 시장 - 세계 및 지역별 분석 : 적응증별, 제품별, 지역별 - 분석과 예측(2022-2032년) PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032
발행일 : 2022년 09월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 PD-1/PDL-1 억제제(PD-1/PDL-1 Inhibitor) 시장에 대해 조사했으며, 시장 개요와 함께 적응증별, 제품별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 시장 정의

제2장 조사 범위

제3장 조사 방법

제4장 시장

  • 시장 개요
  • PD-1/PDL-1 억제제 : 개요
    • PD-1/PDL-1 억제제와 암 면역요법에서의 그 역할
    • PD-1/PDL-1 억제제의 역사적 개발
    • PD-1/PDL-1 억제제의 작용기서
    • 시장 상황
    • 시장 역학

제5장 적응증

  • 적응증
    • 비소세포폐암(NSCLC)
    • 흑색종
    • 간세포암(HCC)
    • 결장직장암(CRC)
    • 유방암
    • 요로상피암

제6장 제품

  • 세계의 PD-1/PDL-1 억제제 파이프라인 분석(상별)
    • 개발 단계별
    • 약물 클래스별
    • 투여 경로별
    • 단독요법·병용요법 종류별
    • 표적별

제7장 지역

  • 북미
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 일본

제8장 시장 - 경쟁 벤치마킹과 기업 개요

  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Arcus Biosciences, Inc.
  • Agenus Inc
  • F. Hoffmann-La Roche Ltd
  • Astra Zeneca PLC
  • Beigene Ltd
  • Shanghai Junshi Bioscience Co. Ltd.
  • Shanghai Henlius Biotech, Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • Lee's Pharmaceutical Limited
  • Incyte Corporation
  • Biocad
  • CStone Pharmaceuticals

제9장 BIS Research의 제안

  • 현재 시장 시나리오
  • 향후 시나리오
  • 주요 성공요인과 과제
    • 성공요인
    • 주요 과제
KSM 22.09.19

List of Figures

  • Figure 1: PD-1/PDL-1 Inhibitor Market Share (by Sales), $Million, 2021
  • Figure 2: Number of Eligible Patients Specific to Indication for 2022
  • Figure 3: Global PD-1/PDL-1 Inhibitor Market Segmentation
  • Figure 4: Global PD-1/PDL-1 Inhibitor Market Methodology
  • Figure 5: Primary Research Methodology
  • Figure 6: Historic Development of PD-1/PDL-1 Inhibitors
  • Figure 7: Role of PD-1/PDL-1 in Tumor Protection
  • Figure 8: Key Market Players (by Sales), $Million, 2021
  • Figure 9: Number of Strategic Activities
  • Figure 10: Regional Distribution of Companies
  • Figure 11: Non-Small Cell Lung Cancer (NSCLC) Disease Pathophysiology
  • Figure 12: Melanoma Disease Pathophysiology
  • Figure 13: Melanoma: Treatment Options
  • Figure 14: Hepatocellular Carcinoma (HCC): Disease Pathophysiology
  • Figure 15: Hepatocellular Carcinoma (HCC) Treatment
  • Figure 16: Hepatocellular Carcinoma (HCC) Treatment Algorithm
  • Figure 17: Chromosomal Instability (CIN) Pathway and Microsatellite Instability (MSI) Pathway
  • Figure 18: Serrated Pathway
  • Figure 19: Colorectal Cancer (CRC): Treatment Algorithm
  • Figure 20: Breast Cancer: Disease Pathophysiology
  • Figure 21: Breast Cancer: Treatment
  • Figure 22: Urothelial Carcinoma: Disease Pathophysiology
  • Figure 23: Urothelial Carcinoma Treatment Types
  • Figure 24: Urothelial Carcinoma Treatment Algorithm
  • Figure 25: Number of PD-1/PDL-1 Inhibitor Clinical Trials
  • Figure 26: Number of Clinical Trials by Drug Class
  • Figure 27: PD-1/PDL-1 Inhibitor by Therapy (Monotherapy/Combination) Type
  • Figure 28: PD-1/PDL-1 Inhibitors with Added Entity
  • Figure 29: U.S. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 30: U.S. Eligible Patient Population for Melanoma, 2022-2032
  • Figure 31: U.S. Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 32: U.S. Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 33: U.S. Eligible Patient Population for NSCLC, 2022-2032
  • Figure 34: U.S. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 35: U.S. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 36: U.K. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 37: U.K. Eligible Patient Population for NSCLC, 2022-2032
  • Figure 38: U.K. Eligible Patient Population for Melanoma, 2022-2032
  • Figure 39: U.K. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 40: U.K. Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 41: U.K. Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 42: U.K. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 43: Germany Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 44: Germany: Eligible Patient Population for NSCLC, 2022-2032
  • Figure 45: Germany: Eligible Patient Population for Melanoma, 2022-2032
  • Figure 46: Germany: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 47: Germany: Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 48: Germany: Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 49: Germany: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 50: France Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 51: France: Eligible Patient Population for NSCLC, 2022-2032
  • Figure 52: France: Eligible Patient Population for Melanoma, 2022-2032
  • Figure 53: France: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 54: France: Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 55: France: Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 56: France: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 57: Italy Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 58: Italy: Eligible Patient Population for NSCLC, 2022-2032
  • Figure 59: Italy: Eligible Patient Population for Melanoma, 2022-2032
  • Figure 60: Italy: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 61: Italy: Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 62: Italy: Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 63: Italy: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 64: Spain Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 65: Spain: Eligible Patient Population for NSCLC, 2022-2032
  • Figure 66: Spain: Eligible Patient Population for Melanoma, 2022-2032
  • Figure 67: Spain: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 68: Spain: Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 69: Spain: Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 70: Spain: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 71: Japan Eligible Population for PD-1/PDL-1 Inhibitor Treatment
  • Figure 72: Japan: Eligible Patient Population for NSCLC, 2022-2032
  • Figure 73: Japan: Eligible Patient Population for Melanoma, 2022-2032
  • Figure 74: Japan: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
  • Figure 75: Japan: Eligible Patient Population for Colorectal Cancer, 2022-2032
  • Figure 76: Japan: Eligible Patient Population for Breast Cancer, 2022-2032
  • Figure 77: Japan: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
  • Figure 78: GlaxoSmithKline plc: Product Portfolio
  • Figure 79: GlaxoSmithKline plc: Overall Financials, $Million, 2019-2021
  • Figure 80: GlaxoSmithKline plc: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 81: GlaxoSmithKline plc: Net Revenue (by Region), $Million, 2019-2021
  • Figure 82: GlaxoSmithKline plc: R&D Expenditure, $Million, 2019-2021
  • Figure 83: Bristol-Myers Squibb Company: Product Portfolio
  • Figure 84: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021
  • Figure 85: Bristol-Myers Squibb Company: Net Revenue (by Region), $Million, 2019-2021
  • Figure 86: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021
  • Figure 87: Arcus Biosciences, Inc.: Product Portfolio
  • Figure 88: Arcus Biosciences, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 89: Arcus Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 90: Agenus Inc.: Product Portfolio
  • Figure 91: Agenus Inc.: Overall Financials, $Million, 2019-2021
  • Figure 92: Agenus Inc.: Net Revenue (by Region), $Million, 2019-2021
  • Figure 93: Agenus Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 94: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 95: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
  • Figure 96: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 97: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
  • Figure 98: Astra Zeneca PLC: Product Portfolio
  • Figure 99: Astra Zeneca PLC: Overall Financials, $Million, 2019-2021
  • Figure 100: Astra Zeneca PLC: Net Revenue (by Region), $Million, 2019-2021
  • Figure 101: Astra Zeneca PLC: R&D Expenditure, $Million, 2019-2021
  • Figure 102: Beigene Ltd.: Product Portfolio
  • Figure 103: Beigene Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 104: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 105: Shanghai Junshi Bioscience Co., Ltd.: Product Portfolio
  • Figure 106: Shanghai Junshi Bioscience Co., Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 107: Shanghai Junshi Bioscience Co., Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 108: Shanghai Henlius Biotech, Inc.: Product Portfolio
  • Figure 109: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 110: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 111: Jiangsu HengRui Medicine Co., Ltd.: Product Portfolio
  • Figure 112: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 113: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 114: Lee's Pharmaceutical Limited: Product Portfolio
  • Figure 115: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
  • Figure 116: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
  • Figure 117: Incyte Corporation: Product Portfolio
  • Figure 118: Incyte Corporation: Overall Financials, $Million, 2019-2021
  • Figure 119: Incyte Corporation R&D Expenditure, $Million, 2019-2021
  • Figure 120: Biocad: Product Portfolio
  • Figure 121: CStone Pharmaceuticals: Product Portfolio
  • Figure 122: CStone Pharmaceuticals: Overall Financials, $Million, 2019-2021
  • Figure 123: CStone Pharmaceuticals: Revenue (by Region), $Million, 2019-2021
  • Figure 124: CStone Pharmaceuticals: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Approved PD-1/PDL-1 Inhibitors
  • Table 2: Snapshot: Approved PD-1/PDL-1 Inhibitors
  • Table 3: Companies by Region
  • Table 4: Number of Indication Added Since Launch
  • Table 5: Combination Regimen with PD-1/PDL-1 Inhibitors
  • Table 6: Non-Small Cell Lung Cancer (NSCLC): Stage Specific Treatment Options
  • Table 7: Stage-Wise Colorectal Cancer (CRC) Treatment
  • Table 8: Systemic Therapy for Distant Recurrence Cases of Colorectal Cancer (CRC)
  • Table 9: PD-1/PDL-1 Inhibitor by Route of Administration (RoA)
  • Table 10: Combination Regimes by Development Stage
  • Table 11: Leading PD-1/PDL-1 Inhibitors and Indications in Combination Therapy
  • Table 12: Leading PD-1/PDL-1 Inhibitors as Monotherapy and Target Indication
  • Table 13: U.S. Incidence for Cancer Indications, 2022-2032
  • Table 14: U.S. Prevalence for Cancer Indications, 2022-2032
  • Table 15: U.K. Incidence for Cancer Indications, 2022-2032
  • Table 16: U.K. Prevalence for Cancer Indications, 2022-2032
  • Table 17: Germany Incidence for Cancer Indications, 2022-2032
  • Table 18: Germany Prevalence for Cancer Indications, 2022-2032
  • Table 19: France Incidence for Cancer Indications, 2022-2032
  • Table 20: France Prevalence for Cancer Indications, 2022-2032
  • Table 21: Italy Incidence for Cancer Indications, 2022-2032
  • Table 22: Italy Prevalence for Cancer Indications, 2022-2032
  • Table 23: Spain Incidence for Cancer Indications, 2022-2032
  • Table 24: Spain Prevalence for Cancer Indications, 2022-2032
  • Table 25: Japan Incidence for Cancer Indications, 2022-2032
  • Table 26: Japan Prevalence for Cancer Indications, 2022-2032
  • Table 27: GlaxoSmithKline plc: Key Competitors
  • Table 28: Product Development
  • Table 29: Partnership and Collaboration
  • Table 30: Potential Registrational Study Readouts Anticipated Through 2023/2024
  • Table 31: Bristol-Myers Squibb Company: Key Competitors
  • Table 32: Product Developments
  • Table 33: Merger and Acquisitions
  • Table 34: Arcus Biosciences, Inc.: Key Competitors
  • Table 35: Product Developments
  • Table 36: Partnerships and Collaboration
  • Table 37: Product Developments
  • Table 38: Partnerships and Collaboration
  • Table 39: F. Hoffmann-La Roche Ltd: Key Competitors
  • Table 40: Product Developments
  • Table 41: Partnership and Collaboration
  • Table 42: Astra Zeneca PLC: Key Competitors
  • Table 43: Product Developments
  • Table 44: Partnership and Collaboration
  • Table 45: Beigene Ltd.: Key Competitors
  • Table 46: Product Developments
  • Table 47: Partnership and Collaboration
  • Table 48: Shanghai Junshi Bioscience Co., Ltd.: Key Competitors
  • Table 49: Product Developments
  • Table 50: Partnership and Collaboration
  • Table 51: Shanghai Henlius Biotech, Inc.: Key Competitors
  • Table 52: Product Developments
  • Table 53: Partnership and Collaboration
  • Table 54: Jiangsu HengRui Medicine Co., Ltd.: Key Competitors
  • Table 55: Product Developments
  • Table 56: Partnership and Collaboration
  • Table 57: Lee's Pharmaceutical Limited: Key Competitors
  • Table 58: Product Developments
  • Table 59: Product Developments
  • Table 60: Collaboration and Agreement
  • Table 61: Product Developments
  • Table 62: Partnership and Collaboration
  • Table 63: Product Developments
  • Table 64: Partnership and Collaboration

BIS Research Study Highlights Melanoma as the most promising indication for the PD-1/PDL-1 Inhibitor therapies in US and EU-5 region while in Japan, Colorectal Cancer (CRC) occupies the position of most promising indication.

Global PD-1/PDL-1 Inhibitor Market Overview

Programmed cell death 1 (PD-1) inhibitor and programmed death ligand 1 (PD-L1) inhibitor are therapeutic agents that inhibit binding together of these checkpoint proteins on immune cells, eventually preventing tumors to escape the host immune defense mechanism and control the disease progression. The first PD-1 inhibitor Opdivo developed by Merck Sharp and Dhome (MSD) entered the market in 2014. Jemperli from GSK is the latest market entrant in the segment.

The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient.

PD-1/PDL-1 inhibitors are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has been found to be more effective in patients demonstrating certain level of predictive biomarkers such as PDL-1 expression. However, these tests are costly and treatment specific which poses a hinderance to smooth administration of these PD-1/PDL-1 inhibitors to larger set of patients.

Several players, such as MSD, Bristol Myers Squibb company (BMS), AstraZeneca Plc are among the leading companies actively pursuing research activities in maximizing the potential of PD-1/PDL-1 inhbitors. Companies in the Asia-Pacific region also have rich clinical pipeline and strategically pursuing research activities in this segment.

Competitive Landscape

There are seven product currently available in the market. The first entrant Keytruda drwas a significant share of the market followed by second entrant Opdivo. Imfinzi and Tecentriq also have their combined market share below 20%.

Disease Landscape

In terms of most promising indication for the application of PD-1/PDL-1 inhibitors, melanoma appears to be leading as highlighted by experts including data gathered from secondary research.

Segmentation:

Within the research report, the segmentation has made on the basis of:

  • Identified cancer indicattions (Non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma), and
  • The seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Demand - Drivers and Challenges

Some of the potential drivers identified by BIS Research includes:

  • Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
  • Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens

The market is expected to face some limitations too due to the following challenges:

  • Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
  • Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment

How can this report add value to an organization?

  • Product/Innovation Strategy: The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications. This can help organizations in understanding the research activities, which is the promising indication to pursue or which organization has the potential product to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit. This report which provides an insight into estimated patient population eligible to receive PD-1/PDL-1 under identified indications will help to evaluate the promising indications.
  • Growth/Marketing Strategy: In addition to pursuing research on exploring the benefits of PD-1/PDL-1 inhibitors in multiple cancer indications, companies are working to bring more safer and convenient PD-1/PDL-1 inhbitors while retaining or improved efficacy. The companies are exploring small molecules as well as alternative formulations for PD-1/PDL-1 inhibitors in an effort to make the administration relatively more convenient.
  • Competitive Strategy: Key players in the global PD-1/PDL-1 inhibitor market were analyzed and profiled in the study, who have commercially available PD-1/PDL-1 inhbitors as well as those who are developing and their products are in the clinical development. Moreover, a detailed competitive benchmarking of the players operating in the global PD-1/PDL-1 inhibitor market has been done to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled:

  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Arcus Biosciences, Inc.
  • Agenus Inc.
  • F. Hoffmann-La Roche Ltd
  • Astra Zeneca PLC
  • Beigene Ltd.
  • Shanghai Junshi Bioscience Co. Ltd.
  • Shanghai Henlius Biotech, Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • Lee's Pharmaceutical Limited
  • Incyte Corporation
  • Biocad
  • Cstone Pharmaceuticals

Table of Contents

1 Market Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global PD-1/PDL-1 Inhibitor Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Target Patient Pool Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets

  • 4.1 Market Overview
  • 4.2 PD-1/PDL-1 Inhibitors: Overview
    • 4.2.1 PD-1/PDL-1 Inhibitors and their role in Cancer immunotherapy
    • 4.2.2 Historic Development of PD-1/PDL-1 Inhibitors
    • 4.2.3 Mechanism of Action of PD-1/PDL-1 Inhibitors
    • 4.2.4 Market Landscape
      • 4.2.4.1 Approved PD-1/PDL-1 Inhibitors
      • 4.2.4.2 Competitive Landscape
        • 4.2.4.2.1 Strategic Activities
        • 4.2.4.2.2 Regional Distribution of Companies
    • 4.2.5 Market Dynamics
      • 4.2.5.1 Market Drivers
        • 4.2.5.1.1 Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
        • 4.2.5.1.2 Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens
      • 4.2.5.2 Market Restraints
        • 4.2.5.2.1 Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
        • 4.2.5.2.2 Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment
      • 4.2.5.3 Opportunities
        • 4.2.5.3.1 Promising Therapeutic Outcomes Generating Positive Market Sentiments
        • 4.2.5.3.2 Demand for Safer and Convenient Formulation

5 Indications

  • 5.1 Indications
    • 5.1.1 Non-Small Cell Lung Cancer (NSCLC)
      • 5.1.1.1 Non-Small Cell Lung Cancer (NSCLC): Disease Overview
      • 5.1.1.2 Non-Small Cell Lung Cancer (NSCLC): Disease Pathophysiology
      • 5.1.1.3 Non-Small Cell Lung Cancer (NSCLC): Treatment
    • 5.1.2 Melanoma
      • 5.1.2.1 Melanoma: Disease Overview
      • 5.1.2.2 Melanoma: Disease Pathophysiology
      • 5.1.2.3 Melanoma: Treatment
    • 5.1.3 Hepatocellular Carcinoma (HCC)
      • 5.1.3.1 Hepatocellular Carcinoma (HCC): Disease Overview
      • 5.1.3.2 Hepatocellular Carcinoma (HCC): Disease Pathophysiology
      • 5.1.3.3 Hepatocellular Carcinoma (HCC): Treatment
    • 5.1.4 Colorectal Cancer (CRC)
      • 5.1.4.1 Colorectal Cancer (CRC): Disease Overview
      • 5.1.4.2 Colorectal Cancer (CRC): Disease Pathophysiology
      • 5.1.4.3 Colorectal Cancer (CRC): Treatment
    • 5.1.5 Breast Cancer
      • 5.1.5.1 Breast Cancer: Disease Overview
      • 5.1.5.2 Breast Cancer: Pathophysiology
      • 5.1.5.3 Breast Cancer: Treatment
    • 5.1.6 Urothelial Carcinoma
      • 5.1.6.1 Urothelial Carcinoma: Disease Overview
      • 5.1.6.2 Urothelial Carcinoma: Pathophysiology
      • 5.1.6.3 Urothelial Carcinoma: Treatment

6 Products

  • 6.1 Global PD-1/PDL-1 Inhibitor Pipeline Analysis (by Phase)
    • 6.1.1 By Development Phase
    • 6.1.2 By Drug Class
    • 6.1.3 By Route of Administration (RoA)
    • 6.1.4 By Monotherapy/Combination Therapy Type
    • 6.1.5 By Target

7 Application

  • 7.1 North America
    • 7.1.1 Melanoma
      • 7.1.1.1 Melanoma: Epidemiology
    • 7.1.2 Breast Cancer
      • 7.1.2.1 Breast Cancer: Epidemiology
    • 7.1.3 Colorectal Cancer (CRC)
      • 7.1.3.1 Colorectal Cancer (CRC): Epidemiology
    • 7.1.4 Non-Small Cell Lung Cancer (NSCLC)
      • 7.1.4.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.1.5 Hepatocellular Carcinoma (HCC)
      • 7.1.5.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.1.6 Urothelial Carcinoma
      • 7.1.6.1 Urothelial Carcinoma: Epidemiology
  • 7.2 U.K.
    • 7.2.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.2.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.2.2 Melanoma
      • 7.2.2.1 Melanoma: Epidemiology
    • 7.2.3 Hepatocellular Carcinoma (HCC)
      • 7.2.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.2.4 Colorectal Cancer (CRC)
      • 7.2.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.2.5 Breast Cancer
      • 7.2.5.1 Breast Cancer: Epidemiology
    • 7.2.6 Urothelial Carcinoma
      • 7.2.6.1 Urothelial Carcinoma: Epidemiology
  • 7.3 Germany
    • 7.3.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.3.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.3.2 Melanoma
      • 7.3.2.1 Melanoma: Epidemiology
    • 7.3.3 Hepatocellular Carcinoma (HCC)
      • 7.3.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.3.4 Colorectal Cancer (CRC)
      • 7.3.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.3.5 Breast Cancer
      • 7.3.5.1 Breast Cancer: Epidemiology
    • 7.3.6 Urothelial Carcinoma
      • 7.3.6.1 Urothelial Carcinoma: Epidemiology
  • 7.4 France
    • 7.4.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.4.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.4.2 Melanoma
      • 7.4.2.1 Melanoma: Epidemiology
    • 7.4.3 Hepatocellular Carcinoma (HCC)
      • 7.4.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.4.4 Colorectal Cancer (CRC)
      • 7.4.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.4.5 Breast Cancer
      • 7.4.5.1 Breast Cancer: Epidemiology
    • 7.4.6 Urothelial Carcinoma
      • 7.4.6.1 Urothelial Carcinoma: Epidemiology
  • 7.5 Italy
    • 7.5.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.5.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.5.2 Melanoma
      • 7.5.2.1 Melanoma: Epidemiology
    • 7.5.3 Hepatocellular Carcinoma (HCC)
      • 7.5.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.5.4 Colorectal Cancer (CRC)
      • 7.5.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.5.5 Breast Cancer
      • 7.5.5.1 Breast Cancer: Epidemiology
    • 7.5.6 Urothelial Carcinoma
      • 7.5.6.1 Urothelial Carcinoma: Epidemiology
  • 7.6 Spain
    • 7.6.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.6.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.6.2 Melanoma
      • 7.6.2.1 Melanoma: Epidemiology
    • 7.6.3 Hepatocellular Carcinoma (HCC)
      • 7.6.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.6.4 Colorectal Cancer (CRC)
      • 7.6.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.6.5 Breast Cancer
      • 7.6.5.1 Breast Cancer: Epidemiology
    • 7.6.6 Urothelial Carcinoma
      • 7.6.6.1 Urothelial Carcinoma: Epidemiology
  • 7.7 Japan
    • 7.7.1 Non-Small Cell Lung Cancer (NSCLC)
      • 7.7.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
    • 7.7.2 Melanoma
      • 7.7.2.1 Melanoma: Epidemiology
    • 7.7.3 Hepatocellular Carcinoma (HCC)
      • 7.7.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
    • 7.7.4 Colorectal Cancer (CRC)
      • 7.7.4.1 Colorectal Cancer (CRC): Epidemiology
    • 7.7.5 Breast Cancer
      • 7.7.5.1 Breast Cancer: Epidemiology
    • 7.7.6 Urothelial Carcinoma
      • 7.7.6.1 Urothelial Carcinoma: Epidemiology

8 Markets - Competitive Benchmarking & Company Profiles

  • 8.1 GlaxoSmithKline plc
    • 8.1.1 Company Overview
    • 8.1.2 Role of GlaxoSmithKline plc in Global PD-1/PDL-1 Inhibitor Market
    • 8.1.3 Product Portfolio
    • 8.1.4 Key Competitors of the Company
    • 8.1.5 Financials
    • 8.1.6 Key Insights About Financial Health of the Company
    • 8.1.7 Business Strategies
      • 8.1.7.1 Product Developments
    • 8.1.8 Corporate Strategies
      • 8.1.8.1 Partnership and Collaboration
    • 8.1.9 Analyst's Perspective
  • 8.2 Bristol-Myers Squibb Company
    • 8.2.1 Company Overview
    • 8.2.2 Role of Bristol-Myers Squibb Company in Global PD-1/PDL-1 Inhibitor Market
    • 8.2.3 Product Portfolio
    • 8.2.4 Key Competitors of the Company
    • 8.2.5 Financials
    • 8.2.6 Key Insights About Financial Health of the Company
    • 8.2.7 Business Strategies
      • 8.2.7.1 Product Developments
    • 8.2.8 Corporate Strategies
      • 8.2.8.1 Merger and Acquisitions
    • 8.2.9 Analyst's Perspective
  • 8.3 Arcus Biosciences, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Role of Arcus Biosciences, Inc. in Global PD 1/PDL-1 inhibitor Market
    • 8.3.3 Product Portfolio
    • 8.3.4 Key Competitors of the Company
    • 8.3.5 Financials
    • 8.3.6 Key Insights About Financial Health of the Company
    • 8.3.7 Business Strategies
      • 8.3.7.1 Product Developments
    • 8.3.8 Corporate Strategies
      • 8.3.8.1 Partnerships and Collaboration
    • 8.3.9 Analyst's Perspective
  • 8.4 Agenus Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Role of Agenus Inc. in Global PD 1/PDL-1 Inhibitor Market
    • 8.4.3 Product Portfolio
    • 8.4.4 Financials
    • 8.4.5 Key Insights About Financial Health of the Company
    • 8.4.6 Business Strategies
      • 8.4.6.1 Product Developments
    • 8.4.7 Corporate Strategies
      • 8.4.7.1 Partnerships and Collaboration
    • 8.4.8 Analyst's Perspective
  • 8.5 F. Hoffmann-La Roche Ltd
    • 8.5.1 Company Overview
    • 8.5.2 Role of F. Hoffmann-La Roche Ltd in Global PD 1/PDL-1 inhibitor Market
    • 8.5.3 Product Portfolio
    • 8.5.4 Key Competitors of the Company
    • 8.5.5 Financials
    • 8.5.6 Key Insights About Financial Health of the Company
    • 8.5.7 Business Strategies
      • 8.5.7.1 Product Developments
    • 8.5.8 Corporate Strategies
      • 8.5.8.1 Partnership and Collaboration
    • 8.5.9 Analyst's Perspective
  • 8.6 Astra Zeneca PLC
    • 8.6.1 Company Overview
    • 8.6.2 Role of Astra Zeneca PLC in Global PD 1/PDL-1 inhibitor Market
    • 8.6.3 Product Portfolio
    • 8.6.4 Key Competitors of the Company
    • 8.6.5 Financials
    • 8.6.6 Key Insights About Financial Health of the Company
    • 8.6.7 Business Strategies
      • 8.6.7.1 Product Developments
    • 8.6.8 Corporate Strategies
      • 8.6.8.1 Partnership and Collaboration
    • 8.6.9 Analyst's Insight
  • 8.7 Beigene Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Role of Beigene Ltd. in Global PD 1/PDL-1 inhibitor Market
    • 8.7.3 Product Portfolio
    • 8.7.4 Key Competitors of the Company
    • 8.7.5 Financials
    • 8.7.6 Key Insights About Financial Health of the Company
    • 8.7.7 Business Strategies
      • 8.7.7.1 Product Developments
    • 8.7.8 Corporate Strategies
      • 8.7.8.1 Partnership and Collaboration
    • 8.7.9 Analyst's Perspective
  • 8.8 Shanghai Junshi Bioscience Co. Ltd.
    • 8.8.1 Company Overview
    • 8.8.2 Role of Shanghai Junshi Bioscience Co., Ltd. in Global PD 1/PDL-1 inhibitor Market
    • 8.8.3 Product Portfolio
    • 8.8.4 Key Competitors of the Company
    • 8.8.5 Financials
    • 8.8.6 Key Insights About Financial Health of the Company
    • 8.8.7 Business Strategies
      • 8.8.7.1 Product Developments
    • 8.8.8 Corporate Strategies
      • 8.8.8.1 Partnership and Collaboration
    • 8.8.9 Analyst's Perspective
  • 8.9 Shanghai Henlius Biotech, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Role of Shanghai Henlius Biotech, Inc. in Global PD 1/PDL-1 inhibitor Market
    • 8.9.3 Product Portfolio
    • 8.9.4 Key Competitors of the Company
    • 8.9.5 Financials
    • 8.9.6 Key Insights About Financial Health of the Company
    • 8.9.7 Business Strategies
      • 8.9.7.1 Product Developments
    • 8.9.8 Corporate Strategies
      • 8.9.8.1 Partnership and Collaboration
    • 8.9.9 Analyst's Perspective
  • 8.1 Jiangsu HengRui Medicine Co., Ltd.
    • 8.10.1 Company Overview
    • 8.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in Global PD 1/PDL-1 Inhibitor Market
    • 8.10.3 Product Portfolio
    • 8.10.4 Key Competitors of the Company
    • 8.10.5 Financials
    • 8.10.6 Key Insights About Financial Health of the Company
    • 8.10.7 Business Strategies
      • 8.10.7.1 Product Developments
    • 8.10.8 Corporate Strategies
      • 8.10.8.1 Partnership and Collaboration
    • 8.10.9 Analyst's Perspective
  • 8.11 Lee's Pharmaceutical Limited
    • 8.11.1 Company Overview
    • 8.11.2 Role of Lee's Pharmaceutical Limited in Global PD 1/PDL-1 inhibitor Market
    • 8.11.3 Product Portfolio
    • 8.11.4 Key Competitors of the Company
    • 8.11.5 Financials
    • 8.11.6 Key Insights About Financial Health of the Company
    • 8.11.7 Business Strategies
      • 8.11.7.1 Product Developments
    • 8.11.8 Analyst's Perspective
  • 8.12 Incyte Corporation
    • 8.12.1 Company Overview
    • 8.12.2 Role of Incyte Corporation in Global PD-1/PDL-1 inhibitors Market
    • 8.12.3 Product Portfolio
    • 8.12.4 Key Competitors of the Company
    • 8.12.5 Financials
    • 8.12.6 Key Insights About Financial Health of the Company
    • 8.12.7 Business Strategies
      • 8.12.7.1 Product Developments
    • 8.12.8 Corporate Strategies
      • 8.12.8.1 Collaboration and Agreement
    • 8.12.9 Analyst's Perspective
  • 8.13 Biocad
    • 8.13.1 Company Overview
    • 8.13.2 Role of Biocad in Global PD-1/PDL-1 Inhibitors Market
    • 8.13.3 Product Portfolio
    • 8.13.4 Key Competitors of the Company
    • 8.13.5 Business Strategies
      • 8.13.5.1 Product Developments
    • 8.13.6 Corporate Strategies
      • 8.13.6.1 Partnership and Collaboration
    • 8.13.7 Analyst's Perspective
  • 8.14 CStone Pharmaceuticals
    • 8.14.1 Company Overview
    • 8.14.2 Role of CStone Pharmaceuticals in Global PD-1/PDL-1 Inhibitors Market
    • 8.14.3 Product Portfolio
    • 8.14.4 Key Competitors of the Company
    • 8.14.5 Financials
    • 8.14.6 Key Insights About Financial Health of the Company
    • 8.14.7 Business Strategies
      • 8.14.7.1 Product Developments
    • 8.14.8 Corporate Strategies
      • 8.14.8.1 Partnership and Collaboration
    • 8.14.9 Analyst's Perspective

9 BIS Research Recommendations

  • 9.1 Current Market Scenario
  • 9.2 Future Scenario
  • 9.3 Key Success Factors and Challenges
    • 9.3.1 Success Factors
    • 9.3.2 Key Challenges
Back to Top
전화 문의
F A Q